

24 February 2014

Australian Securities Exchange
Companies Announcements Office
SYDNEY

Bioxyne Limited completes sale of HI-164OV Program to Mariposa Health Limited

Bioxyne Limited (ASX code: BXN or the Company) advises that it has entered into a Share Sale and Purchase Agreement and Royalty Agreement and has completed the sale of its wholly owned subsidiary, Hunter Immunology Pty Limited (HIPL), which holds the COPD (Congestive Obstructive Pulmonary Disease) related HI-164 Oral Vaccine Intellectual Property of the Company to Mariposa Health Limited (MHL).

The consideration received was as anticipated per the Company's announcement to the ASX on 2 December 2013.

Reiterating, the consideration for the sale and purchase of up to \$1.56 million, comprises the following mix of cash and equity:

- a. Cash on completion of \$157,500. A deposit of \$17,500 was previously received on execution of the Heads of Agreement. Total cash consideration of \$175,000;
- b. Assumption of a debt in HIPL by MHL of ~\$60,000;
- c. Consideration equity in MHL to the value of \$325,000 at a deemed price of 16.5 cents per share (equivalent to 5% shareholding in MHL on a diluted basis);
- d. Deferred consideration of \$1 million on commercialisation of HI-164OV by MHL subject to agreed clinical and financial milestones within the next 5 years;
- e. On successful commercialisation of HI-164OV, an ongoing Royalty ranging from 2% to 6.5% of gross revenue, depending on the prospective structure of the commercialisation.

With the divestment of its HI-164OV program, the Company will continue with its sales and distribution of probiotics products and research and development of its Intellectual Property in:

(a) Golden Staph; and

(b) Candida.

BXN is continuing with its acquisition strategy of advanced stage research projects to broaden the operational base of the Company.

Bioxyne Chairman Tony Ho said, "As a substantial shareholder of MHL, we will be working with Dr. Phillip Comans and his team to support their endeavours to successfully commercialise HI-164OV. We are pleased that shareholders of BXN are able to continue maintaining an ongoing interest in the future development and commercialisation of HI-164OV".

Mariposa Health Limited holds a number of COPD related research and development programs. The acquisition of HI-164OV would complement MHL's portfolio of COPD research programs. MHL is founded by Dr. Phillip Comans

For more information contact:

Tony Ho
+61 417 345 839
Chairman